DRAFT MANUSCRIPT 1 Title: Use of viral load to improve survey estimates of known HIV-positive status and 2 antiretroviral treatment coverage 3 Running head: Adjusting survey estimates with viral load 4 Peter W. YOUNG^{1,§}. Emily ZIELINSKI-GUTIERREZ¹. Joyce WAMICWE². Irene MUKUI². 5 Andrea A. KIM³, Anthony WARURU¹, Clement ZEH³, Mirjam E. KRETZSCHMAR^{4,5}, Kevin M. 6 DE COCK¹ 7 ¹ Division of Global HIV & TB, U.S. Centers for Disease Control and Prevention, 8 Nairobi, Kenya 9 ² National AIDS & STI Control Programme, Ministry of Health, Kenya 10 ³ Division of Global HIV & TB, U.S. Centers for Disease Control and Prevention, 11 Atlanta, GA, USA 12 ⁴ Julius Center for Health Sciences and Primary Care, University Medical Center 13 Utrecht (UMCU), Utrecht, the Netherlands 14 ⁵ Centre for Infectious Disease Control, National Institute of Public Health and the 15 Environment (RIVM), Bilthoven, The Netherlands 16 17 Abstract length: 227 words (limit 250) 18 Paper length: 1769 words (limit 1800) 19 S Corresponding author and requests for reprints: Peter Wesley Young 20 PO Box 606 21 Village Market 22 Nairobi, Kenya 00601 23 Email: Pyoung1@cdc.gov phone: +254728608673 24 25 26 E-mail addresses of authors: PWY: pyoung1@cdc.gov 27 28 EZG: ebz0@cdc.gov 29 JW: jwamicwe@yahoo.co.uk IM: irenemukui5@gmail.com 30 AAK: bwd2@cdc.gov 31 32 AW: ivg3@cdc.gov 33 CZ: cbz2@cdc.gov MEK: M.E.E.Kretzschmar@umcutrecht.nl 34 35 KDC: kmd2@cdc.gov 36 37

39

40 41

42 43

44 45

46

47 48

49

50

51 52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

Conflicts of interest and source of funding: The 2012 Kenya AIDS Indicator Survey has been supported by the President's Emergency Plan for AIDS Relief (PEPFAR) through the U.S. Centers for Disease Control and Prevention (CDC) under the terms of #PS001805, GH000069, and PS001814. The survey was also funded in part by support from the Global Fund, World Bank, and the Joint United Nations Programme on HIV/AIDS. A portion of this analysis has been presented as a poster at the 2019 International AIDS Society (IAS) conference (http://programme.ias2019.org/Abstract/Abstract/4626). Disclaimer: The findings and conclusions in this manuscript are those of the author(s) and do not necessarily represent the official position of the Centers for Disease Control and Prevention and other funding institutions. The authors declare no conflicts of interest. **Abstract** Objective: To compare alternative methods of adjusting self-reported knowledge of HIVpositive status and antiretroviral (ARV) therapy use based on undetectable viral load (UVL) and ARV detection in blood. **Design:** Post hoc analysis of nationally-representative household survey to compare alternative biomarker-based adjustments to population HIV indicators. Methods: We reclassified HIV-positive participants aged 15-64 years in the 2012 Kenya AIDS Indicator Survey (KAIS) that were unaware of their HIV-positive status by self-report as aware and on antiretroviral treatment if either ARVs were detected or viral load was undetectable (<550 copies/mL) on dried blood spots. We compared self-report to adjustments for ARVs measurement, UVL, or both. Results: Treatment coverage among all HIV-positive respondents increased from 31.8% for self-report to 42.5% [95% confidence interval (CI) 37.4-47.8] based on ARV detection alone, to 42.8% (95% CI 37.9-47.8) when ARV-adjusted, 46.2% (95% CI 41.3-51.1) when

UVL-adjusted and 48.8% (95% CI 43.9–53.8) when adjusted for either ARV or UVL. 67 68 Awareness of positive status increased from 46.9% for self-report to 56.2% (95% CI 50.7– 69 61.6) when ARV-adjusted, 57.5% (95% CI 51.9-63.0) when UVL-adjusted, and 59.8% (95% 70 CI 54.2-65.1) when adjusted for either ARV or UVL. Conclusions: Undetectable viral load, which is routinely measured in surveys, may be a 71 72 useful adjunct or alternative to ARV detection for adjusting survey estimates of knowledge of HIV status and antiretroviral treatment coverage. 73 74 75 Abstract length: 227 words 76 Keywords: HIV surveillance, antiretroviral treatment, population surveys, biomarkers, 77 Kenya 78

Introduction

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97

98

99

100

101

102

103

Since the 2007 Kenya AIDS Indicator Survey (KAIS), HIV seroprevalence surveys have often included questions on knowledge of HIV status and antiretroviral (ARV) use among HIV-infected respondents, as well as biomarkers such as viral load (VL) [1-3] and ARV testing. Self-reported knowledge of status and antiretroviral treatment (ART) status can be subject to either positive or negative social desirability bias in some respondents [4] due to the stigma associated with HIV [5,6]. Some respondents may also have inaccurate recall or understanding of detailed questions about their HIV testing and care histories [7]. Antiretroviral testing can be used to adjust self-reported HIV status by reclassifying respondents with ARVs detected in their blood as being previously diagnosed and on ART [8,9]. In the 2012 KAIS 46.9% of HIV-infected respondents self-reported that they were aware of their HIV-positive status, but ARVs were also detected in 21.0% of those not reporting prior HIV diagnosis and 19.3% of those reporting no previous HIV test. However, antiretroviral testing is relatively complex, expensive, and only available within a very limited number of specialized laboratories worldwide, necessitating international shipping, resulting in additional cost, administrative paperwork, and potential for delays. Unlike ARV testing, which is added exclusively to correct self-reported HIV status and ART use, viral load testing is widely available and routinely included in surveys to estimate population viral suppression (defined as VL < 1000 copies/mL [10]). Undetectable viral load (UVL) is generally indicative of viral suppression due to treatment, hence it could serve as an alternative, indirect marker for treatment. Although the presence of elite controllers (EC) who have UVL in the absence of treatment could confound use of UVL as a proxy for ART use, in US and European cohorts EC are believed to represent only 0.15-1.5% of the HIV-infected population [11], while in East African settings similarly low prevalence of EC has been observed [12,13], limiting the potential impact of this confounding.

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

Given viral load testing is already conducted routinely in HIV surveys, we examined whether adjusting estimates of knowledge of HIV-positive status and ART coverage using a measure of viral load would achieve similar results to adjustments based on detection of ARVs in a national household survey conducted in Kenya in 2012. Methods The 2012 KAIS included behavioral questions including self-reported HIV and ART status as well as collection of venous blood from which DBS were prepared by field teams and plasma separated and shipped for HIV testing at a national laboratory [2]. After participating in other survey procedures, participants were offered rapid HIV testing by trained HIV counselors in their homes with immediate return of results based on national HIV testing guidelines [14]. Participants testing positive for HIV at the central laboratory were subsequently tested for viral load using the Abbott M2000 platform on DBS subsequently stored at -80°C for future testing. In 2015, DBS were shipped to the University of Cape Town for testing for presence of efavirenz, nevirapine, lopinavir or lamivudine by liquid chromatography tandem mass spectrometry (limit of detection 0.02) µg/mL) [15]. These ARVs were selected to cover first- and second-line regimens in use in Kenya at the time of specimen collection [8,16,17]. We retrospectively re-analyzed survey data to compare self-reported and biomarker-adjusted versions of knowledge of status and ART use among HIV-infected respondents aged 15-64 years. Measures We defined UVL as having a viral load <550 copies/mL on dried blood spots, the limit of detection for the assay used in the study [18]. To calculate UVL-adjusted status, we updated the status for those respondents categorized as 'unaware' or 'aware, not on ART' with undetectable viral load

to 'aware, on ART'. Similarly, ARV-adjusted status was calculated by updating the status for

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

respondents with ARVs detected in blood to 'aware, on ART'. For either case, the status for respondents with missing biomarker results was not updated. We explored differences in self-reported, ARV-adjusted, and UVL-adjusted indicators by age, sex, marital status, educational attainment and mobility. Results were analyzed in R version 3.5.0 [19] using the survey package [20] to adjust and weight results to account for the complex survey design. Wald confidence intervals for survey indicators were calculated on the logarithmic scale and transformed to probability scale using the 'logit' method of the svyciprop function in R; confidence intervals previously reported by Kim et al. [21] were calculated on the probability scale. **Ethical considerations** The 2012 KAIS was approved by the University of California, San Francisco, the U.S. Centers for Disease Control (CDC) in Atlanta, GA, USA and the Kenya Medical Research Institute. Prior to household and individual interviews and blood collection written consent was obtained: in the case of children aged less than 18 years assent was sought in addition to permission from their caregiver or guardian. Results Among 648 HIV-infected respondents, self-reported status was 'unaware' among 343 (53.1%), 'aware, not on ART' among 100 (15.1%), and 'aware, on ART' among 205 (31.8%) (Supplemental Table S1). Of those with UVL and unaware of their HIV-positive status by self-report, 40 also had ARVs detected in blood (Supplemental Table S2). Antiretroviral treatment coverage among all HIV-infected increased from 31.8% (95% CI 27.3-36.6) based on self-report to 42.8% (95% CI 37.9–47.8) when combining self-report and ARV detection, to 46.2% (95% CI 41.3–51.1) when combining self-report and UVL, and finally to 48.8% (95% CI 43.9-53.8) with self-report, UVL or ARVs combined (Table 1). Changes in ART coverage were consistent across demographic

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

characteristics, although the 15-24 year age group saw greater increases when adjusted compared to other age groups (Supplemental Figure S1). Knowledge of status increased from 46.9% (95% CI 41.4-52.4) based on self-report to 56.2% (95% CI 50.7–61.6) when adjusting with ARVs, to 57.5% (95% CI 51.9–63.0) when adjusting for UVL, and to 59.8% (95% CI 54.2–65.1) when adjusting for either ARV or UVL (Table 2). Similar to population ART coverage, ART among those with known HIV-positive status also increased from self-report to adjustment, with similar increases between adjustment methods. The youngest age group also saw the biggest impact of adjustment versus self-report for these indicators in both relative and absolute terms. We repeated the analysis excluding the respondents for whom either the ARV or UVL biomarkers were not available; findings were similar (Supplemental Table S3). **Discussion** In order to balance resources between finding undiagnosed HIV infections, linking patients to HIV treatment, and ensuring retention and adherence to care it is necessary to obtain the best possible estimates of knowledge of HIV-positive status and ART use. We set out to establish whether viral load, a routinely-available marker in HIV surveys, can be used to adjust selfreported estimates of knowledge of HIV-positive status and ART use. In KAIS 2012, UVL-adjusted point estimates were similar to, but slightly greater than ARV-adjusted estimates of knowledge of status and ART coverage, suggesting adjustment with UVL might have been sufficient. When measuring ART coverage, all of the adjusted estimates (ARV only, UVL only, and either ARV or UVL) had overlapping confidence intervals, but are notably higher than estimates based on selfreport alone. The change in estimates when adjusting by ARVs and UVL were similar across demographic

groups, but 15-24 year olds did see a larger additional increase when adjusting by UVL. This may

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

199

indicate poor recent adherence in this group leading to non-detection of the ARV biomarker but undetectable viral load (<550 copies/mL in this study). Li et al found that 37% of patients still had a viral load <200 copies/mL four weeks after interrupting ART [22]. Many ARVs reach undetectable levels in blood within several days of treatment interruption [8,15,23], thus in populations with poor adherence or high rates of treatment interruption, adjusting based on UVL may result in higher estimated ART coverage than measures incorporating ARV detection. The performance of UVL for adjusting ART use will depend on the prevalence of UVL in the population on HIV treatment. In populations with effective ART programs with high rates of viral suppression in the treated population, it may be a relatively sensitive marker for ART use; however, in populations with poor treatment outcomes a larger proportion of patients on treatment would not have UVL. The prevalence of elite controllers has not been established in Kenya, hence it is not possible to quantify their influence on the UVL-adjusted estimates, but given the similarity between UVLadjusted and ARV-adjusted estimates, their potential impact was limited. Simultaneously adjusting for either UVL or presence of ARVs may in fact be closest to true population prevalence of the indicators of interest. Without better data on prevalence of elite controllers in this population it is more conservative to use one or the other marker rather than both combined. In settings with ample evidence of low prevalence of elite control, or where population high ART coverage and immediate treatment initiation means even elite controllers are likely to be on treatment, using the combined indicator would likely represent the most sensitive approach to estimating population-based knowledge of status and ART coverage. This analysis was subject to several limitations. While adjusting for biomarkers associated with ARV exposure from a single time-point can account for misreporting of status among those on ART, it cannot account for those who misreport their knowledge of HIV-positive status but are not currently on treatment, or those who may be on treatment but transiently non-adherent to

medications. Other established methods for reducing bias in self-reported estimates, such as computer-assisted self-interview methods, may also be helpful [24]. This analysis was based on data from a single country with low ART coverage (43.5%) and viral suppression among those on treatment (73.9%) at the time of the survey compared with current program coverage; the UVL adjustment may perform differently in other populations. Simulation or replication of this analysis in a diverse set of populations, including the more recent population-based HIV impact assessments conducted in many countries, could help elucidate the performance of UVL adjustment in different settings. Finally, poor specimen quality could result in false-negative results for both biomarkers. In spite of these limitations, this analysis does strongly suggest that use of UVL to adjust self-reported HIV status and ART use should be considered, especially in surveys where the inclusion of the ARV biomarker may be cost-prohibitive or subject to delays.

Conclusion

Streamlining the estimation of key HIV program indicators should allow governments, donors and other stakeholders to assess program performance more quickly and affordably. Viral load, which is routinely measured in HIV surveys, may be a useful biomarker for adjusting self-reported indicators of HIV diagnosis and treatment in cross-sectional surveys in absence of, or in addition to, adjustment based on detected ARVs in blood.

219

220

221

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

Acknowledgements We would like to thank the University of Cape Town Department of Clinical Pharmacology for conducting the ART biomarker testing, the National HIV Reference Laboratory for conducting the KAIS 2012 viral load testing, the study teams that collected data in the field, and finally the survey participants. **Competing interests** All authors declare no competing interests. Authors' contributions PWY, EZG and KDC conceived the study. PWY conducted the analyses. All authors contributed to drafting and critical review of the manuscript. **Additional files** Additional file 1. Supplementary tables and figures Word document containing additional supplementary analyses referenced in text. References 1 2007 Kenya AIDS Indicator Survey Final Report. Nairobi, Kenya: National AIDS and STI Control Programme (NASCOP); 2009. http://stacks.cdc.gov/view/cdc/12122/ 2 Waruiru W, Kim AA, Kimanga DO, Ng'ang'a J, Schwarcz S, Kimondo L, et al. The Kenya AIDS Indicator Survey 2012: rationale, methods, description of participants, and response rates. J Acquir Immune Defic Syndr 2014; **66 Suppl 1**:S3-12. 3 Brown K, Williams DB, Kinchen S, Saito S, Radin E, Patel H, et al. Status of HIV Epidemic

239		Control Among Adolescent Girls and Young Women Aged 15–24 Years — Seven African
240		Countries, 2015–2017. MMWR. Morb. Mortal. Wkly. Rep. 2018.
241		doi:10.15585/mmwr.mm6701a6
242	4	Kelly CA, Hewett PC, Mensch BS, Rankin JC, Nsobya SL, Kalibala S, et al. Using biomarkers
243		to assess the validity of sexual behavior reporting across interview modes among young
244		women in Kampala, Uganda. Stud Fam Plann Published Online First: 2014.
245		doi:10.1111/j.1728-4465.2014.00375.x
246	5	Bonnington O, Wamoyi J, Ddaaki W, Bukenya D, Ondenge K, Skovdal M, et al. Changing
247		forms of HIV-related stigma along the HIV care and treatment continuum in sub-Saharan
248		Africa: A temporal analysis. Sex Transm Infect 2017; 93 :1–6.
249	6	Gurmu E, Etana D. HIV/AIDS knowledge and stigma among women of reproductive age in
250		Ethiopia. <i>African J AIDS Res</i> 2015; 14 :191–199.
251	7	Mooney AC, Campbell CK, Ratlhagana M-J, Grignon JS, Mazibuko S, Agnew E, et al. Beyond
252		Social Desirability Bias: Investigating Inconsistencies in Self-Reported HIV Testing and
253		Treatment Behaviors Among HIV-Positive Adults in North West Province, South Africa.
254		AIDS Behav 2018; 22 :2368–2379.
255	8	Kim AA, Mukui I, Young PW, Mirjahangir J, Mwanyumba S, Wamicwe J, et al. Undisclosed
256		HIV infection and ART use in the Kenya AIDS indicator survey 2012: relevance to targets for
257		HIV diagnosis and treatment in Kenya. AIDS 2016; 30:2685–2695.
258	9	Huerga H, Shiferie F, Grebe E, Giuliani R, Farhat J Ben, Van-Cutsem G, et al. A comparison
259		of self-report and antiretroviral detection to inform estimates of antiretroviral therapy
260		coverage, viral load suppression and HIV incidence in Kwazulu-Natal, South Africa. BMC
261		Infect Dis 2017; 17 :1–8.

262	10	Global AIDS Monitoring 2018: Indicators for monitoring the 2016 United Nations Political
263		Declaration on Ending AIDS. Geneva, Switzerland: UNAIDS; 2017.
264		https://www.unaids.org/sites/default/files/media_asset/2017-Global-AIDS-
265		Monitoring_en.pdf
266	11	Gonzalo-Gil E, Ikediobi U, Sutton RE. Mechanisms of virologic control and clinical
267		characteristics of HIV+ elite/viremic controllers. <i>Yale J Biol Med</i> 2017; 90 :245–259.
268	12	Kayongo A, Gonzalo-Gil E, Gümüşgöz E, Niwaha AJ, Semitala F, Kalyesubula R, <i>et al.</i>
269		Identification of Elite and Viremic Controllers from a Large Urban HIV Ambulatory Center in
270		Kampala, Uganda. <i>JAIDS J Acquir Immune Defic Syndr</i> 2018; 79 :394–398.
271	13	Kiros Y, Elinav H, Gebreyesus A, Gebremeskel H, Azar J, Chemtob D, et al. Identification and
272		characterization of HIV positive Ethiopian elite controllers in both Africa and Israel. HIV
273		<i>Med</i> 2018; :1–5.
274	14	National Guidelines for HIV Testing and Counseling in Kenya. 2nd ed. Nairobi, Kenya:
274 275	14	National Guidelines for HIV Testing and Counseling in Kenya. 2nd ed. Nairobi, Kenya: National AIDS and STI Control Programme (NASCOP); 2010.
	14 15	
275		National AIDS and STI Control Programme (NASCOP); 2010.
275 276		National AIDS and STI Control Programme (NASCOP); 2010. Koal T, Burhenne H, Römling R, Svoboda M, Resch K, Kaever V. Quantification of
275276277		National AIDS and STI Control Programme (NASCOP); 2010. Koal T, Burhenne H, Römling R, Svoboda M, Resch K, Kaever V. Quantification of antiretroviral drugs in dried blood spot samples by means of liquid
275276277278		National AIDS and STI Control Programme (NASCOP); 2010. Koal T, Burhenne H, Römling R, Svoboda M, Resch K, Kaever V. Quantification of antiretroviral drugs in dried blood spot samples by means of liquid chromatography/tandem mass spectrometry. <i>Rapid Commun Mass Spectrom</i> 2005;
275276277278279	15	National AIDS and STI Control Programme (NASCOP); 2010. Koal T, Burhenne H, Römling R, Svoboda M, Resch K, Kaever V. Quantification of antiretroviral drugs in dried blood spot samples by means of liquid chromatography/tandem mass spectrometry. <i>Rapid Commun Mass Spectrom</i> 2005; 19:2995–3001.
275276277278279280	15	National AIDS and STI Control Programme (NASCOP); 2010. Koal T, Burhenne H, Römling R, Svoboda M, Resch K, Kaever V. Quantification of antiretroviral drugs in dried blood spot samples by means of liquid chromatography/tandem mass spectrometry. <i>Rapid Commun Mass Spectrom</i> 2005; 19:2995–3001. Moyo S, Young PW, Gouws E, Naidoo I, Wamicwe J, Mukui I, <i>et al.</i> Equity of antiretroviral
275276277278279280281	15	National AIDS and STI Control Programme (NASCOP); 2010. Koal T, Burhenne H, Römling R, Svoboda M, Resch K, Kaever V. Quantification of antiretroviral drugs in dried blood spot samples by means of liquid chromatography/tandem mass spectrometry. <i>Rapid Commun Mass Spectrom</i> 2005; 19:2995–3001. Moyo S, Young PW, Gouws E, Naidoo I, Wamicwe J, Mukui I, <i>et al.</i> Equity of antiretroviral treatment use in high HIV burden countries: Analyses of data from nationally-

285		content/uploads/2013/04/Kenya_National-ARV-Guidelines_2011.pdf
286	18	Zeh C, Ndiege K, Inzaule S, Achieng R, Williamson J, Chang JCW, et al. Evaluation of the
287		performance of Abbott m2000 and Roche COBAS Ampliprep/COBAS Taqman assays for
288		HIV-1 viral load determination using dried blood spots and dried plasma spots in Kenya.
289		PLoS One Published Online First: 2017. doi:10.1371/journal.pone.0179316
290	19	R Core Team. R: A Language and Environment for Statistical Computing.
291		2018.https://www.r-project.org/
292	20	Lumley T. survey: analysis of complex survey samples. 2017.
293	21	Kim AA, Mukui I, Young PW, Mirjahangir J, Mwanyumba S, Wamicwe J, et al. Undisclosed
294		HIV infection and antiretroviral therapy use in the Kenya AIDS indicator survey 2012:
295		Relevance to national targets for HIV diagnosis and treatment. AIDS 2016; 30.
296		doi:10.1097/QAD.00000000001227
297	22	Li JZ, Etemad B, Ahmed H, Aga E, Bosch RJ, Mellors JW, et al. The size of the expressed HIV
298		reservoir predicts timing of viral rebound after treatment interruption. AIDS 2016; 30 :343–
299		353.
300	23	Jackson A, Moyle G, Watson V, Tjia J, Ammara A, Back D, et al. Tenofovir, emtricitabine
301		intracellular and plasma, and efavirenz plasma concentration decay following drug intake
302		cessation: Implications for HIV treatment and prevention. J Acquir Immune Defic Syndr
303		Published Online First: 2013. doi:10.1097/QAI.0b013e3182829bd0
304	24	Gnambs T, Kaspar K. Disclosure of sensitive behaviors across self-administered survey
305		modes: a meta-analysis. Behav Res Methods Published Online First: 2014.
306		doi:10.3758/s13428-014-0533-4

Table 1. Self-reported and adjusted estimates of ART coverage among people living with HIV, KAIS 2012

													Self-ı	reporte	ed,
	Self-reported (N=648)			А	ARV only (N=559)			Self-report or ARV (N=648)			Self-report or UVL (N=648)			or UV	'L
				((N=648)	
Characteristic	n	%	se	n	%	se	n	%	se	n	%	se	n	%	se
Sex															
Male	51	27.0	3.7	64	37.8	4.7	74	39.9	4.5	78	41.9	4.4	84	44.3	4.5
Female	154	34.7	2.5	171	45.6	2.6	198	44.6	2.5	217	48.8	2.5	230	51.6	2.5
Age group															
15–24 yrs	6	7.1	2.7	11	21.6	6.4	14	20.7	5.8	19	28.8	6.2	20	29.9	6.2
25–34 yrs	48	21.1	3.1	50	25.1	3.6	65	29.3	3.5	65	28.2	3.3	76	33.9	3.6
35–49 yrs	104	41.1	3.9	121	55.0	3.8	133	52.9	3.6	147	58.2	3.4	152	59.5	3.3
50–64 yrs	47	48.0	5.4	53	59.6	5.6	60	60.6	5.3	64	64.0	5.0	66	65.5	5.0
Marital status															
Single/never married	16	16.7	4.0	18	24.5	5.9	22	23.8	5.1	29	32.5	5.6	31	33.9	5.7

Married/cohabitating	118	31.4	3.2	141	42.0	3.4	163	43.3	3.2	175	46.1	3.1	186	48.6	3.2
Divorced /sep /	71	41.5	4.0	76	53.1	4.3	87	52.6	4.0	91	54.2	3.9	97	58.1	4.0
widowed															
Highest educational															
attainment															
None	28	33.2	5.8	31	35.5	5.9	39	44.6	6.0	39	45.2	6.0	41	46.5	6.0
Primary	94	26.7	2.8	111	39.5	3.6	126	38.4	3.3	137	40.8	3.3	148	44.3	3.5
Secondary	10	31.4	10.2	14	45.7	10.1	15	43.7	9.8	16	50.7	9.3	18	54.9	9.6
Higher	73	40.8	4.3	78	50.6	5.0	91	50.2	4.4	102	55.8	4.2	106	57.2	4.1
Employment															
unemployed	82	36.2	4.3	91	50.0	4.6	106	47.6	4.3	114	50.6	4.3	118	52.2	4.2
employed	123	29.6	2.6	144	39.0	2.8	166	40.5	2.8	181	44.0	2.7	196	47.2	2.8
Mobility															
Not away for >1	112	31.2	3.0	126	42.0	3.5	146	42.2	3.2	156	44.5	3.3	166	46.8	3.2
month in last year															

Away >1 month in last	87	32.1	3.4	101	43.7	4.0	117	43.7	3.6	129	48.0	3.7	137	51.4	3.9
year															
Total	205	31.8	2.4	235	42.5	2.6	272	42.8	2.5	295	46.2	2.5	314	48.8	2.5

Note: self-reported: self-report only, ARV-only: based on presence/absence of ARVs only, self-report or ARV: either self-reported known-positive/on ART or ARVs detected, self-report or UVL: either self-reported known-positive/on ART or viral load was undetectable, self-report, ARV or UVL: either self-reported known-positive/on ART, ARVs detected, or UVL, N: unweighted denominator, n: unweighted numerator, se: standard error. Missing biomarker results were treated as biomarker not present. Percentages and standard errors are weighted and adjusted to account for the survey design.

Table 2. Self-reported and adjusted estimates of HIV care cascade, KAIS 2012

Characteristic		Se	Self-report			eport or A	RV	Self-re	port or U	VL	Self-report, ARV or UVL			
Variable	Level	n	%	se	n	%	se	n	%	se	n	%	se	
Awareness	of HIV infection	n (1st 90)												
Gender	Male	73	38.0	4.3	92	49.5	4.9	95	50.7	4.9	99	52.6	5.0	
	Female	232	52.2	2.8	268	60.4	2.6	275	61.7	2.5	286	64.2	2.5	
Age group	15-24 yrs	16	18.0	5.0	24	31.7	6.5	27	37.7	7.0	28	38.8	7.0	
	25–34 yrs	88	41.1	4.3	102	48.2	4.3	102	46.7	4.3	111	52.0	4.3	
	35–49 yrs	144	55.9	3.8	167	65.7	3.4	172	67.6	3.3	176	68.5	3.3	
	50-64 yrs	57	56.9	5.5	67	66.4	5.2	69	68.0	5.0	70	68.7	5.0	
Total		305	46.9	2.8	360	56.2	2.8	370	57.5	2.8	385	59.8	2.8	
ART covera	ge among prev	iously-diag	gnosed (2	nd 90)										
Gender	Male	51	71.0	5.8	74	80.7	4.5	78	82.5	4.0	84	84.2	3.9	
	Female	154	66.4	3.3	198	73.9	3.0	217	79.1	2.7	230	80.4	2.6	

Age group	15-24 yrs	6	39.3	10.4	14	65.5	10.0	19	76.3	7.3	20	77.0	7.1	
	25–34 yrs	48	51.2	5.8	65	60.9	5.3	65	60.3	5.3	76	65.2	5.1	
	35–49 yrs	104	73.6	4.4	133	80.5	3.7	147	86.2	2.7	152	86.8	2.6	
	50–64 yrs	47	84.3	5.2	60	91.3	3.8	64	94.1	2.7	66	95.5	2.3	
Total		205	67.9	3.2	272	76.2	2.8	295	80.2	2.3	314	81.7	2.3	
Viral load < 1000 copies/mL among those on ART (3rd 90)														
Gender	Male	35	72.8	6.3	52	75.9	5.1	62	82.5	4.3	62	78.4	4.6	
	Female	115	76.6	3.8	146	75.4	3.5	178	83.5	2.8	178	78.8	2.9	
Age group	15-24 yrs	2	34.6	19.8	9	72.4	11.3	15	83.9	7.4	15	80.8	7.9	
	25–34 yrs	29	57.3	8.2	35	50.0	7.3	46	68.4	6.7	46	57.0	6.6	
	35–49 yrs	84	84.5	3.8	108	85.6	3.3	127	89.1	2.7	127	87.2	2.9	
	50–64 yrs	35	74.9	6.6	46	77.5	5.7	52	81.2	5.2	52	79.2	5.3	
Total		150	75.4	3.3	198	75.6	2.8	240	83.1	2.3	240	78.6	2.5	

Note: self-reported: self-report only, self-report or ARV: either self-reported known-positive/on ART or ARVs detected, self-report or UVL:

either self-reported known-positive/on ART or viral load was undetectable, self-report, ARV or UVL: either self-reported known-

positive/on ART, ARVs detected, or UVL, n: unweighted numerator, se: standard error, viral suppression defined as <1000 copies/mL.

Missing biomarker results were treated as biomarker not present. Percentages and standard errors are weighted and adjusted to account for the survey design. The unweighted denominators can vary due to adjustment for the 2nd and 3rd 90 and for each indicator/measure combination are as follows: 1st 90: 305 for all measures, 2nd 90: 360 for self-report or ARV, 370 for self-report or UVL, 385 for self-report, ARV or UVL.